Carlsmed Inc(CARL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.35 | Insider Own | 62.59% | Shs Outstand | 27.2M | Perf Week | 7.94% |
| Market Cap | 0.43B | Forward P/E | - | EPS next Y | 3.44% | Insider Trans | -0.01% | Shs Float | 10.2M | Perf Month | 12.08% |
| Enterprise Value | 0.36B | PEG | - | EPS next Q | -0.39 | Inst Own | 21.21% | Short Float | 10.72% | Perf Quarter | 25.26% |
| Income | -0.04B | P/S | 6.8 | EPS this Y | 31.42% | Inst Trans | 2.28% | Short Ratio | 9.68 | Perf Half Y | 77.39% |
| Sales | 0.06B | P/B | 5.1 | EPS next 5Y | 22.16% | ROA | -42.39% | Short Interest | 1.09M | Perf YTD | 27.69% |
| Book/sh | 3.09 | P/C | 4.82 | EPS past 3/5Y | -26.24% - | ROE | -66.14% | 52W High | -8.47% ($17.23) | Perf Year | 26.06% |
| Cash/sh | 3.27 | P/FCF | - | Sales past 3/5Y | 91.47% - | ROIC | -34.46% | 52W Low | 85.53% ($8.50) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -39.1% | Gross Margin | 76.63% | Volatility(W/M) | 5.62% 5.45% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 5.74 | Sales Y/Y TTM | 65.39% | Oper. Margin | -61.09% | ATR (14) | 0.79 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 8.66 | EPS Q/Q | -46.74% | Profit Margin | -57.42% | RSI (14) | 62.39 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.84 | Sales Q/Q | 56.75% | SMA20 | 8.68% ($14.51) | Beta | 2.08 | Target Price | $19.4 |
| Payout | - | Debt/Eq | 0.26 | Earnings | 2026/11/10 | SMA50 | 4.72% ($15.06) | Rel Volume | 0.52 | Prev Close | $15.31 |
| Employees | 127 | LT Debt/Eq | 0.25 | EPS/Sales Surpr. | 1.52% 5.26% | SMA200 | 27.25% ($12.39) | Avg Volume(3M) | 0.11M | Price | $15.77 |
| IPO | 2025/7/23 | Option/Short | No/Yes | Trades | 1032 | Volume | 58,644 | Change | 3% |
A US medical technology company developing AI-based, patient-tailored spine surgery solutions. Through its aprevo platform, it provides both pre-surgical planning and patient-specific implants, and is a growth-stage company in commercialization that is rapidly expanding its surgeon user base in the lumbar and cervical fusion surgery fields.
Over the past 1 year, on the higher side
8% below its 1-year high.
Traded less than usual. That is 52% of its average volume.
Next earnings report: November 10
11 days to go.
CARL has a sound balance sheet but weak earning power
Of every $100 in sales, $61.09 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +31.4% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $680. Peers typically go for $181.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 21.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #22 of 41 in the industry
Based on market cap of $431M.
FAQ
What kind of company is CARL?
CARL belongs to the Healthcare sector and operates in the Health Information Services industry.
What is the market cap of CARL?
The market cap of CARL is approximately $431M, ranking 3,287 within its sector.
What is the 52-week high and low for CARL?
CARL has recorded a 52-week high of $17.23 and a low of $8.50.
